Indian pharmaceutical company Piramal Pharma Ltd (PPL) (NSE:PPLPHARMA) (BSE:543635) announced on Tuesday that it has completed the acquisition of an incremental 40.67% stake in Yapan Bio Private Limited, a Hyderabad-based CDMO specialising in vaccines and biologics for an aggregate cash consideration of INR760m, or USD7.95m.

As a result of this transaction, PPL now owns 74% of Yapan Bio's equity, making the business a subsidiary of PPL.

PPL intends to fully embed Yapan Bio's advanced large molecule capabilities into its integrated service offering, enabling the company to offer customers broader services in the space and expanding its ability to develop and scale complex biologic therapies with greater efficiency. The subsidiary will continue to operate within the structure of Piramal Pharma Solutions (PPS), PPL's CDMO arm.

Yapan Bio also directly supports ADCelerate, PPS's fixed-price, integrated platform that streamlines Phase I ADC development from R&D to GMP in as little as 12 months.